Odonate Reports Clinically Meaningful PFS Improvement In CONTESSA Study Of Tesetaxel

(RTTNews) - Odonate Therapeutics, Inc. (ODT) reported positive top-line results from CONTESSA, a Phase 3 study of tesetaxel in patients with metastatic breast cancer. CONTESSA met the primary endpoint of improved progression free survival. While overall survival data are not mature, a recent interim analysis indicated the absence of an adverse effect, the company noted. A final analysis of overall survival is expected to occur in 2022.

The company plans to submit a New Drug Application for tesetaxel to the FDA in mid-2021.

Shares of Odonate Therapeutics were up 8% in pre-market trade on Monday.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.